Nicholas Potter - Epigenomics Director Reimbursement and Medical Affairs
Director
Mr. Nicholas T. Potter, Ph.D., was Director Reimbursement and Medical Affairs of Epigenomics AG since November 1, 2017. Most recently, he spent over 14 years at MPLN, Inc. in Maryville, TN as the Laboratory Director of Molecular Diagnostics, CSO, and finally EVP of Clinical Affairs. At the executive level at MPLN he played a pivotal role in driving value and strategic growth by pursuing business partnerships with IVD manufacturers, BioPharma, molecular diagnostics companies, and other CLIA certifiedCAP accredited laboratories to allow access to new platforms, technologies, MDx tests, and clinical trials in addition to leading payment efforts focusing on women health, genomics, oncology and personalized medicine. Additionally, over this time frame, he served as a CAP inspector for molecular diagnostic laboratories. He received his Ph.D. from Duke University in immunology in 1986 following his undergraduate education at Bucknell University. He held postgraduate positions at Harvard, University of Connecticut and the University of Tennessee where he maintains a faculty appointment. since 2017.
| Tenure | 7 years |
| Phone | 49 30 243 450 |
| Web | https://www.epigenomics.com |
Epigenomics Management Efficiency
The company has return on total asset (ROA) of (0.245) % which means that it has lost $0.245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3802) %, meaning that it generated substantial loss on money invested by shareholders. Epigenomics' management efficiency ratios could be used to measure how well Epigenomics manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 966 K in total debt with debt to equity ratio (D/E) of 0.07, which may suggest the company is not taking enough advantage from borrowing. Epigenomics AG has a current ratio of 3.8, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Epigenomics until it has trouble settling it off, either with new capital or with free cash flow. So, Epigenomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Epigenomics AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Epigenomics to invest in growth at high rates of return. When we think about Epigenomics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jonathan Sheena | Natera Inc | 45 | |
| Xiaoying Mai | Twist Bioscience Corp | 30 | |
| Aaref Hilaly | Guardant Health | 46 | |
| Stanley Meresman | Guardant Health | 71 | |
| James Borel | Neogen | 62 | |
| Karin Eastham | Illumina | 67 | |
| Nelson Chan | Twist Bioscience Corp | 57 | |
| James Tobin | Neogen | 61 | |
| Frederick Craves | Twist Bioscience Corp | 72 | |
| Samir Kaul | Guardant Health | 44 | |
| Arthur Bowman | Illumina | 69 | |
| Michael Byron | Burning Rock BiotechLtd | 55 | |
| John Thompson | Illumina | 68 | |
| Roy Baynes | Natera Inc | 63 | |
| Ian Clark | Guardant Health | 57 | |
| Roy Whitfield | Illumina | 63 | |
| Jack Parnell | Neogen | 82 | |
| Robert Ragusa | Twist Bioscience Corp | 58 | |
| Frances Arnold | Illumina | 61 | |
| Werner Brandt | Qiagen NV | 61 | |
| James Healy | Natera Inc | 53 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 |
Epigenomics AG Leadership Team
Elected by the shareholders, the Epigenomics' board of directors comprises two types of representatives: Epigenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epigenomics. The board's role is to monitor Epigenomics' management team and ensure that shareholders' interests are well served. Epigenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epigenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antje Zeise, Manager Investor Relations | ||
| Guenther Reiter, Member of the Supervisory Board | ||
| Gregory Hamilton, CEO Board | ||
| Ann Kessler, Member of the Supervisory Board | ||
| Jens Ravens, CFO Board | ||
| Heino Prondzynski, Chairman of the Supervisory Board | ||
| Helge Lubenow, Member of the Supervisory Board | ||
| Thomas Taapken, CEO, CFO and Member of Executive Board | ||
| Annett Dietrich, Manager Human Resources | ||
| Noel Doheny, CEO of Epigenomics Inc. | ||
| Andrew Lukowiak, Pres Officer | ||
| Uwe Staub, COO and Member of Executive Board | ||
| Albert Weber, Sr. VP of Fin., Accounting and Controlling | ||
| Frederic Hilke, Investor Officer | ||
| Nicola HennebergBusse, Vice President - Business Development | ||
| Jorge Garces, President Chief Scientific Officer | ||
| Nicholas Potter, Director Reimbursement and Medical Affairs | ||
| Peter Vogt, Investor & Public Relations Officer |
Epigenomics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Epigenomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 4.09 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 4.86 % | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 0.39 X | |||
| Price To Sales | 10.64 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Epigenomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Epigenomics' short interest history, or implied volatility extrapolated from Epigenomics options trading.
Pair Trading with Epigenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epigenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epigenomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Epigenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epigenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epigenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epigenomics AG to buy it.
The correlation of Epigenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epigenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epigenomics AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epigenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Other Tools for Epigenomics Pink Sheet
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |